Erasca(NASDAQ) ERAS

Erasca, Inc. makes medicine for people with cancer. It targets specific pathways that cause tumors to grow. These treatments aim to help patients live longer.

Fighting Cancer at the Source

• ERAS-0015: Orally administered drug designed to block specific cancer-driving signals in solid tumors; currently in Phase 1 clinical testing.
• ERAS-4001: Experimental drug that inhibits a protein called KRAS to stop tumor growth; undergoing Phase 1 clinical trials.
• ERAS-12: Discovery-stage antibody program designed to target receptors on the surface of cancer cells.

Strategic Moves in Precision Medicine

• In-licensed a franchise focused on RAS genetic mutations in May 2024 to expand the clinical pipeline.
• Entered a clinical trial collaboration with Tango Therapeutics in March 2026 to evaluate combined drug therapies.
• Established a supply agreement with Merck in May 2026 to use the immunotherapy pembrolizumab in clinical trials.
• Ended a license agreement with Novartis in June 2026 to focus internal resources on other cancer programs.

What Makes Erasca Different

Erasca targets the RAS/MAPK pathway, which is one of the most frequently altered signaling routes in human cancer. The company uses a multimodal approach to select the most effective drug type for specific genetic mutations.

Funding the Research Journey

• Net loss was $44.1 million for the three-month period ended June 30, 2026.
• In-process research and development expenses reached $150.0 million during the six-month period ended June 30, 2026.
• Cash, cash equivalents, and marketable securities totaled $384.3 million as of June 30, 2026.
• Net proceeds from a common stock offering in July 2026 were $593.5 million.
• Accumulated deficit grew to $1.1 billion by June 30, 2026.

Bottom Line

Erasca has evolved from a discovery-stage startup to a clinical-stage oncology firm. Its recent funding and focused pipeline provide resources to test potential treatments in humans.